Komipharm Applies for Phase 2/3 Clinical Trial Plan of COVID-19 Treatment in Italy
[Asia Economy Reporter Kum Boryeong] Comipharm announced on the 25th that it has applied to the Italian Medicines Agency (AIFA) for a Phase 2/3 clinical trial plan to evaluate the safety and efficacy of PAX-1 (Panapix) in pneumonia patients caused by the novel coronavirus infection (COVID-19).
The clinical trial will involve a total of 794 patients infected with COVID-19 from Italy, Spain, and Russia. The trial period is 28 days in total.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Comipharm stated, "PAX-1 suppresses the release of various inflammatory cytokines involved in the pathogenesis of viral infectious diseases, such as TNF-α, IL-1β, and IL-6, from immune cells," and added, "PAX-1 plans to verify its effectiveness in preventing and treating pneumonia and acute respiratory distress syndrome (ARDS) caused not only by COVID-19 but also by other viral and influenza infectious diseases in the future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
